Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Contineum Therapeutics, Inc. stock logo
CTNM
Contineum Therapeutics
$6.95
+3.0%
$4.81
$3.35
$20.55
$179.81M1.04130,992 shs80,516 shs
Hyperion DeFi, Inc. stock logo
HYPD
Hyperion DeFi
$7.04
-2.6%
$8.81
$0.85
$75.18
$39.42M2.422.11 million shs472,836 shs
Lifevantage Corporation stock logo
LFVN
Lifevantage
$14.51
+2.5%
$12.94
$7.09
$27.38
$182.68M0.45199,421 shs90,026 shs
Liminatus Pharma Inc. stock logo
LIMN
Liminatus Pharma
$4.40
+1.1%
$0.00
$4.10
$33.66
$114.44MN/A529,124 shs316,634 shs
 The Best Nuclear Energy Stocks to Buy Cover

Nuclear energy stocks are roaring. It's the hottest energy sector of the year. Cameco Corp, Paladin Energy, and BWX Technologies were all up more than 40% in 2024. The biggest market moves could still be ahead of us, and there are seven nuclear energy stocks that could rise much higher in the next several months. To unlock these tickers, enter your email address below.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Contineum Therapeutics, Inc. stock logo
CTNM
Contineum Therapeutics
+4.98%+12.50%+72.19%+75.78%-61.03%
Hyperion DeFi, Inc. stock logo
HYPD
Hyperion DeFi
-7.66%+33.89%-45.35%+512.71%-89.71%
Lifevantage Corporation stock logo
LFVN
Lifevantage
+2.91%+5.36%+17.90%+12.74%+80.15%
Liminatus Pharma Inc. stock logo
LIMN
Liminatus Pharma
-2.90%-11.94%-34.59%+434,999,900.00%+434,999,900.00%
CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
Contineum Therapeutics, Inc. stock logo
CTNM
Contineum Therapeutics
2.9592 of 5 stars
3.63.00.00.03.80.80.6
Hyperion DeFi, Inc. stock logo
HYPD
Hyperion DeFi
0.3037 of 5 stars
1.00.00.00.02.40.80.6
Lifevantage Corporation stock logo
LFVN
Lifevantage
4.2355 of 5 stars
3.50.01.72.73.22.51.3
Liminatus Pharma Inc. stock logo
LIMN
Liminatus Pharma
N/AN/AN/AN/AN/AN/AN/AN/A
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Contineum Therapeutics, Inc. stock logo
CTNM
Contineum Therapeutics
3.17
Buy$22.50223.74% Upside
Hyperion DeFi, Inc. stock logo
HYPD
Hyperion DeFi
2.00
Hold$2.00-71.59% Downside
Lifevantage Corporation stock logo
LFVN
Lifevantage
3.00
Buy$30.50110.20% Upside
Liminatus Pharma Inc. stock logo
LIMN
Liminatus Pharma
0.00
N/AN/AN/A

Current Analyst Ratings Breakdown

Latest HYPD, LFVN, LIMN, and CTNM Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
6/20/2025
Contineum Therapeutics, Inc. stock logo
CTNM
Contineum Therapeutics
William Blair
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Initiated CoverageOutperform
5/19/2025
Contineum Therapeutics, Inc. stock logo
CTNM
Contineum Therapeutics
Morgan Stanley
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetOverweight ➝ Overweight$25.00 ➝ $20.00
5/15/2025
Contineum Therapeutics, Inc. stock logo
CTNM
Contineum Therapeutics
Royal Bank Of Canada
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingOutperform ➝ Outperform$31.00 ➝ $31.00
(Data available from 8/13/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Contineum Therapeutics, Inc. stock logo
CTNM
Contineum Therapeutics
N/AN/AN/AN/A$6.62 per shareN/A
Hyperion DeFi, Inc. stock logo
HYPD
Hyperion DeFi
$60K657.07N/AN/A($695.52) per share-0.01
Lifevantage Corporation stock logo
LFVN
Lifevantage
$200.16M0.91$0.93 per share15.60$2.05 per share7.08
Liminatus Pharma Inc. stock logo
LIMN
Liminatus Pharma
N/AN/AN/AN/AN/AN/A
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Contineum Therapeutics, Inc. stock logo
CTNM
Contineum Therapeutics
-$42.26M-$2.20N/AN/AN/AN/A-29.75%-28.08%N/A
Hyperion DeFi, Inc. stock logo
HYPD
Hyperion DeFi
-$49.82M-$58.40N/AN/AN/A-62,238.41%N/A-316.90%N/A
Lifevantage Corporation stock logo
LFVN
Lifevantage
$2.94M$0.6921.03N/A4.12%34.67%15.24%8/27/2025 (Estimated)
Liminatus Pharma Inc. stock logo
LIMN
Liminatus Pharma
N/AN/A0.00N/AN/AN/AN/AN/A

Latest HYPD, LFVN, LIMN, and CTNM Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
8/27/2025Q4 2025
Lifevantage Corporation stock logo
LFVN
Lifevantage
$0.17N/AN/AN/A$57.93 millionN/A
8/13/2025Q2 2025
Hyperion DeFi, Inc. stock logo
HYPD
Hyperion DeFi
N/A-$2.50N/A-$2.50N/AN/A
8/5/2025Q2 2025
Contineum Therapeutics, Inc. stock logo
CTNM
Contineum Therapeutics
-$0.56-$0.62-$0.06-$0.62$7.50 millionN/A
5/19/2025Q1 2025
Hyperion DeFi, Inc. stock logo
HYPD
Hyperion DeFi
-$7.20-$1.59+$5.61-$1.59$1.60 million$1.60 million
5/14/2025Q1 2025
Contineum Therapeutics, Inc. stock logo
CTNM
Contineum Therapeutics
-$0.56-$0.62-$0.06-$0.62$7.50 millionN/A
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Contineum Therapeutics, Inc. stock logo
CTNM
Contineum Therapeutics
N/AN/AN/AN/AN/A
Hyperion DeFi, Inc. stock logo
HYPD
Hyperion DeFi
N/AN/AN/AN/AN/A
Lifevantage Corporation stock logo
LFVN
Lifevantage
$0.181.24%N/A26.09%3 Years
Liminatus Pharma Inc. stock logo
LIMN
Liminatus Pharma
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Contineum Therapeutics, Inc. stock logo
CTNM
Contineum Therapeutics
N/A
24.51
24.51
Hyperion DeFi, Inc. stock logo
HYPD
Hyperion DeFi
N/A
0.34
0.34
Lifevantage Corporation stock logo
LFVN
Lifevantage
N/A
1.66
0.98
Liminatus Pharma Inc. stock logo
LIMN
Liminatus Pharma
N/AN/AN/A

Institutional Ownership

CompanyInstitutional Ownership
Contineum Therapeutics, Inc. stock logo
CTNM
Contineum Therapeutics
N/A
Hyperion DeFi, Inc. stock logo
HYPD
Hyperion DeFi
25.84%
Lifevantage Corporation stock logo
LFVN
Lifevantage
35.32%
Liminatus Pharma Inc. stock logo
LIMN
Liminatus Pharma
N/A

Insider Ownership

CompanyInsider Ownership
Contineum Therapeutics, Inc. stock logo
CTNM
Contineum Therapeutics
11.30%
Hyperion DeFi, Inc. stock logo
HYPD
Hyperion DeFi
10.86%
Lifevantage Corporation stock logo
LFVN
Lifevantage
20.65%
Liminatus Pharma Inc. stock logo
LIMN
Liminatus Pharma
N/A
CompanyEmployeesShares OutstandingFree FloatOptionable
Contineum Therapeutics, Inc. stock logo
CTNM
Contineum Therapeutics
3125.87 million22.95 millionN/A
Hyperion DeFi, Inc. stock logo
HYPD
Hyperion DeFi
405.60 million5.00 millionOptionable
Lifevantage Corporation stock logo
LFVN
Lifevantage
26012.59 million9.99 millionOptionable
Liminatus Pharma Inc. stock logo
LIMN
Liminatus Pharma
N/A26.01 millionN/AN/A

New MarketBeat Followers Over Time

Media Sentiment Over Time

Contineum Therapeutics stock logo

Contineum Therapeutics NASDAQ:CTNM

$6.95 +0.20 (+2.96%)
Closing price 04:00 PM Eastern
Extended Trading
$6.94 -0.02 (-0.22%)
As of 05:50 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Contineum Therapeutics, Inc., a clinical stage biopharmaceutical company, focuses on discovering and developing novel oral small molecule therapies for neuroscience, inflammation, and immunology indications with high unmet need. Its lead asset is PIPE-791, a novel, brain penetrant, small molecule inhibitor of the lysophosphatidic acid 1 receptor (LPA1R) for the treatment of idiopathic pulmonary fibrosis and progressive multiple sclerosis (MS). The company also develops PIPE-307, a novel, small molecule selective inhibitor of the muscarinic type 1 M1 receptor to treat depression and relapse remitting MS; and CTX-343, a peripherally-restricted LPA1R antagonist. Contineum Therapeutics, Inc. was formerly known as Pipeline Therapeutics, Inc. and changed its name to Contineum Therapeutics, Inc. in November 2023. The company was incorporated in 2009 and is headquartered in San Diego, California.

Hyperion DeFi stock logo

Hyperion DeFi NASDAQ:HYPD

$7.04 -0.19 (-2.63%)
As of 04:00 PM Eastern

Eyenovia, Inc., an ophthalmic technology company, engages in the development of therapeutics based on its proprietary microdose array print platform technology. The company's product candidates include MicroPine, which is in Phase III clinical development program with indications for pediatric myopia progression (near-sightedness); MicroLine, which is in Phase III clinical development program with indications for the improvement in near vision in people with presbyopia; and Mydcombi, which is in Phase III clinical development program with indications for pharmaceutical mydriasis. It has a license agreement with Bausch Health Ireland Limited to develop and commercialize MicroPine in the United States and Canada; a license agreement with Arctic Vision (Hong Kong) Limited to develop and commercialize MicroPine, MicroLine, and Mydcombi in China and South Korea; and Senju Pharmaceutical Co., Ltd. to develop and commercialize MicroPine, MicroLine, and Mydcombi. The company was formerly known as PGP Holdings V, Inc. and changed its name to Eyenovia, Inc. in May 2014. Eyenovia, Inc. was incorporated in 2014 and is based in New York, New York.

Lifevantage stock logo

Lifevantage NASDAQ:LFVN

$14.51 +0.35 (+2.47%)
Closing price 04:00 PM Eastern
Extended Trading
$14.70 +0.19 (+1.31%)
As of 04:46 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

LifeVantage Corporation engages in the identification, research, development, formulation, and sale of advanced nutrigenomic activators, dietary supplements, nootropics, pre- and pro-biotics, weight management, skin and hair care, bath and body, and targeted relief products. It offers Protandim, a dietary supplement; LifeVantage Omega+, a dietary supplement that combines DHA and EPA Omega-3 fatty acids, Omega-7 fatty acids, and vitamin D3; LifeVantage ProBio, a dietary supplement to support gut health; PhysIQ, a weight management system; LifeVantage IC Bright, a supplement to support eye and brain health, reduce eye fatigue and strain, supports cognitive functions, and support normal sleep patterns; Petandim for Dogs, a supplement to combat oxidative stress in dogs; and Axio, a nootropic energy drink mix. The company also provides anti-aging skin care products, including liquid collagen, facial cleansers, perfecting lotions, eye serums, anti-aging creams, hand creams, beauty serum, as well as hair care products, such as invigorating shampoos, nourishing conditioners, and scalp serums under the LifeVantage TrueScience brand name. In addition, it offers bath and body, and targeted relief products, such as body lotion, body wash, body butter, deodorant, soothing balm, and body rub under the TrueScience brand name. It sells its products through its website and network of independent distributors in the United States, Mexico, Japan, Australia, Hong Kong, Canada, Thailand, the United Kingdom, the Netherlands, Germany, Taiwan, Austria, Spain, Ireland, Belgium, New Zealand, Singapore, and the Philippines. The company was founded in 2003 and is headquartered in Lehi, Utah.

Liminatus Pharma stock logo

Liminatus Pharma NASDAQ:LIMN

$4.40 +0.05 (+1.15%)
As of 04:00 PM Eastern

Liminatus Pharma, Inc. is a pre-clinical-stage immuno-oncology company, which engages in developing novel, immune-modulating cancer therapies. The company was founded on November 1, 2020 and is headquartered in La Palma, CA.